1. Levin, B. et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002, 95, 1618–1628.
2. Ladabaum, U.; Song, K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 2005, 129, 1151–1162.
3. Hill, L.B.; O’Connell, J.B.; Ko, C.Y. Colorectal cancer: epidemiology and health services research. Surg. Oncol. Clin. N. Am. 2006, 15, 21–37.
4. Ries, L.A.G.; Eisner, M.P.; Kosary, C.L. SEER Cancer Statistics Review. National Cancer Institute 
5. American Cancer Society. Colorectal cancer facts & figures, special edition. Atlanta, Georgia: American Cancer Society, 2007.
6. Anthony, T. Colorectal cancer follow-up in 2005. Surg. Oncol. Clin. N. Am. viii (2006), 15, 175–193.
7. Graffner, H.; Hultberg, B.; Johansson, B.; Moller, T.; Petersson, B.G. Detection of recurrent cancer of the colon and rectum. J. Surg. Oncol. 1985, 28, 156–159.
8. Renehan, A.G.; Egger, M.; Saunders, M.P.; O’Dwyer, S.T. Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br. J. Cancer 2005, 92, 430–433.
9. Secco, G.B. et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur. J. Surg. Oncol. 2002, 28, 418–423.
10. Pietra, N. et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis. Colon. Rectum. 1998, 41, 1127–1133.
11. Kitagawa, Y. et al. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology 2002, 40, 472–479.
12. Maestranzi, S.; Przemioslo, R.; Mitchell, H.; Sherwood, R.A. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 1998, 35 (Pt 1), 99–103.
13. Paganuzzi, M. et al. Carcinoembryonic antigen (CEA) in serum and bile of colorectal cancer patients with or without detectable liver metastases. Anticancer. Res. 1994, 14, 1409–1412.
14. Bell, H.; Orjasaeter, H. Five years’ follow-up of patients with elevated carcinoembryonic antigen (CEA) and alcoholic liver disease, with special reference to mortality rate and development of malignancy. Hepatogastroenterology 1983, 30, 140–142.
15. Charalabopoulos, K. et al. CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers. Med. Oncol. 2007, 24, 219–225.
16. Loewenstein, M.S.; Zamcheck, N. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states. Cancer 1978, 42, 1412–1418.
17. Ladenson, J.H.; McDonald, J.M.; Landt, M.; Schwartz, M.K. (Washington University Case Conference). Colorectal carcinoma and carcinoembryonic antigen (CEA). Clin. Chem. 1980, 26, 1213–1220.
18. Wang, J.Y.; Tang, R.; Chiang, J.M. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon. Rectum. 1994, 37, 272–277.
19. Wang, W.S. et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn. J. Clin. Oncol. 2000, 30, 12–16.
20. Okholm, M.; Iversen, L.H.; Thorlacius-Ussing, O.; Ejlersen, E.; Boesby, S. Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Dis. Colon. Rectum. 1996, 39, 1102–1106.
21. Hatton, M.W. et al. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity. J. Lab. Clin. Med. 2004, 143, 241–254.
22. Hatton, M.W. et al. Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors. J. Lab. Clin. Med. 2006, 147, 27–35.
23. Baker, E.A.; Bergin, F.G.; Leaper, D.J. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol. Pathol. 2000, 53, 307–312.
24. Cohen, R.L. et al. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood 1991, 78, 479–487.
25. Stephens, R.W. et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst. 1999, 91, 869–874.
26. Nakasaki, T. et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am. J. Hematol. 2002, 69, 247–254.
27. Seto, S. et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000, 88, 295–301.
28. Shigemori, C. et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb. Haemost. 1998, 80, 894–898.
29. Versteeg, H.H.; Spek, C.A.; Peppelenbosch, M.P.; Richel, D.J. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol. Med. 2004, 10, 6–11.
30. Nguyen, Q.D. et al. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment. Oncogene 2005, 24, 8240–8251.
31. Pepe, M. The Statistical Evaluation of Medical Tests for Classification and Prediction. In Oxford Statistical Science Series 31; New York: Oxford University Press, 2003.
32. Schaffrath, M. et al. Ovarian Carcinoma: Clinical Validity by Simultaneous Determination of Fibrin Degradation Products with the DR-70 TM Immunoassay and CA-125. German J. Obstetrics and Gynocology 2006, 66, 68–75.
33. Li, X.; Qiao, Z.; Long, X.; Wei, J.; Cheng, Y. Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br. J. Oral. Maxillofac. Surg. 2005, 43, 513–515.
34. Kerber, A. et al. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol. Ther. 2004, 20, 983–987.
35. Wu, D. et al. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J. Immunoassay 1998, 19, 63–72.
36. Ding, L.; Ping, S.; Jingmei, Y. Application of tumor marker of DR-70 (R) in the diagnosis of malignant tumors. Chongqing Med. J. 1999, 28, 1–3.
37. Wu, D.F. et al. Sensitivity & Specificity of DR-70 Lung Cancer Immunoassay. Analytical Letters 1999, 32, 1351–1362.
38. Aliustaoglu, M. et al. D-dimer–can it be a marker for malignant gastric lesions? Acta. Oncol. 2004, 43, 770–771.
39. Rucker, P.; Antonio, S.M.; Braden, B. Elevated Fibrinogen-Fibrin Degradation Products (FDP) in Serum of Colorectal Cancer Patients. Analytical Letters 2004, 37, 2965–2976.
40. Lee, K.-H.; Cho, D.; Kim, K.-M.; Kim, S.-M.; Lee, D.-J. Meaning of the DR-70 TM Immunoassay for Patients with the Malignant Tumor. Immune Network 2006, 6, 43–51.
41. Xu, G.; Zhang, Y.L.; Huang, W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J. Gastroenterol. 2004, 10, 922–923.
42. Oya, M.; Akiyama, Y.; Yanagida, T.; Akao, S.; Ishikawa, H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg. Today 1998, 28, 373–378.
43. Dirix, L.Y. et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br. J. Cancer 2002, 86, 389–395.
44. Lengyel, E. et al. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene 1997, 14, 2563–2573.
45. De Sousa, L.P. et al. Plasminogen=plasmin regulates c-fos and egr-1 expression via the MEK=ERK pathway. Biochem. Biophys. Res. Commun. 2005, 329, 237–245.
46. Dvorak, H.F. Thrombosis and cancer. Hum. Pathol. 1987, 18, 275–284.
47. Esumi, N.; Fan, D.; Fidler, I.J. Inhibition of murine melanoma experimental metastasis by recombi- nant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res. 1991, 51, 4549–4556.
48. Saksela, O.; Rifkin, D.B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell. Biol. 1988, 4, 93–126.
49. Schmitt, M. et al. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol. Chem. Hoppe Seyler 1992, 373, 611–622.
50. Dvorak, H.F. et al. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab. Invest. 1987, 57, 673–686.
51. Thompson, W.D. et al. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J. Pathol. 1992, 168, 47–53.
52. Ruf, W. et al. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol. Res. 2000, 21, 289–292.
53. Desrosiers, R.R.; Cusson, M.H.; Turcotte, S.; Beliveau, R. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration. Int. J. Cancer 2005, 114, 702–712.
54. Dvorak, H.F. et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann. N. Y. Acad. Sci. 1992, 667, 101–111.
55. Gasic, G.J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984, 3, 99–114.
56. Yan, L.; Kumagai, S.G.; McGuire, M.H.; Yee, J.A. Protease activity and invasion of matrigel by the osteosarcoma-derived OSPR cell line. Biochem. Soc. Trans. 1994, 22, 18S.
57. Matsuyama, W. et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000, 118, 948–951.
58. Kim, H.K. et al. Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis 2004, 15, 9–13.
59. Oya, M.; Akiyama, Y.; Okuyama, T.; Ishikawa, H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn. J. Clin. Oncol. 2001, 31, 388–394.
60. Blackwell, K. et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J. Clin. Oncol. 2000, 18, 600–608.
61. Tomimaru, Y. et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J. Am. Coll. Surg. 2006, 202, 139–145.
62. Blackwell, K. et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004, 101, 77–82.
63. Unsal, E.; Atalay, F.; Atikcan, S.; Yilmaz, A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir. Med. 2004, 98, 93–98.
64. Buccheri, G.; Torchio, P.; Ferrigno, D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003, 97, 3044–3052.
65. Blackwell, K.L. et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin. Cancer Res. 2004, 10, 4083–4088.
66. Pavey, S.J.; Hawson, G.A.; Marsh, N.A. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 2001, 12, 51–58.
67. Hron, G. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007, 97, 119–123.